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Pathologic hyperpermeability exists in the spectrum of disease states, including neuro-ischemic, neuro-inflammatory
and neuro-oncological. To-date the characterization of disease pathology with T1-weighted quantitative dynamic
contrast-enhanced magnetic resonance imaging has relied on the study of modeled microvascular parameters such
as diseased tissue transvascular flow rates of small molecule paramagnetic imaging agents with short plasma
half-lives, based on which it is difficult to assess the specific nature of the disease state. Another type of
T1-weighted quantitative dynamic contrast-enhanced magnetic resonance imaging involves the use of paramagnetic
heavy metal-chelated dendrimer nanoparticles that possess longer plasma half-lives with pre-determined molar
relaxivities to quantitatively image concentration of macromolecular contrast agent accumulation over time in
hyperpermeable pathology such as solid tumor tissue with the important advantage of concomitantly treating
the pathology, which, in recent years, has been shown to be possible with the use of optimally-sized theranostic
dendrimer nanoparticles in the 7 to 10 nanometer size range that are functionalized biocompatibly with a small
molecule therapeutic. In this focused review, this translational theranostic methodology for quantitative dynamic
contrast-enhanced magnetic resonance imaging and the concomitant treatment of malignant solid tumors with
optimally designed theranostic nanoparticles within the 7 to 10 nanometer size range is discussed in context
of fine-tuning its suitability for the study and treatment of other disease states with pathologic hyperpermeability
and without.
Keywords: Nanoparticle, Functionalized dendrimer, Quantitative magnetic resonance imaging, Bi-compartmental
modeling, Intravenous administration, Drug delivery, Blood half-life, Pathologic angiogenesis, Primary brain tumor,
MetastasesIntroduction
Pathologic angiogenesis is a hallmark of hyperpermeable
disease states of chromic hypoxia, particularly solid ma-
lignancies, irrespective of type or grade, with there being a
physiologic upper limit of pore size greater than that of
normal healthy tissue blood capillaries with few exceptions
[1-3]. In other disease states of hyperpermeability such
as neuro-ischemic disease the character of microvascular
barrier dysfunction depends on the time course of hyp-
oxia, whereby acute ischemia results in cytotoxic edema
and in secondarily altered diffusion of water molecules
within the tissue interstitia [4] followed by varying periods
of endothelial cell dysfunction and compromised inter-Correspondence: hsmd74@hotmail.com
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unless otherwise stated.endothelial junctional complex integrity of varying degrees
[5], as may be the case in the hyperpermeability of neuro-
inflammatory disease.
Diagnostic imaging with hydrophilic contrast agents
enables the detection of pathologic hyperpermeability in
the form of abnormal contrast enhancement of the diseased
tissue interstitium. This abnormal contrast enhancement of
diseased tissue is observable following the intravenous infu-
sion of hydrophilic small molecule contrast agents but re-
quires administration at relatively high doses, of tens of
grams of the hydrophilic small molecule contrast agent,
and often necessitates the intra-arterial or intra-thecal ad-
ministration due to the non-selectivity of these contrast
agents combined with their relatively short plasma half-
lives, which is irrespective of imaging modality, whetheran Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tomography (PET) or magnetic resonance imaging (MRI).
Furthermore, due to the sub-optimal pharmacokinetico-
dyamics of small molecule contrast agents and the re-
quirement for the administration of high doses, the issue
of systemic toxicity arises and is not uncommon, which
can manifests as systemic hypersensitivity, either as imme-
diate or delayed, depending on the biophysical properties
of the contrast agent, whereby contrast agents such
as Omnipaque 370, an iodinated hexol for CT, can cause
immediate-type hypersensitivity reactions, while those
such as gadopentetate dimeglumine (Magnevist) or gado-
diamide (Omniscan), both being poorly chelated forms
of polyvalent heavy metal Gadolinium (Gd3+) cause
delayed–type hypersensitivity [6], in contrast to when
Gd3+ is introduced into the biological system in its
much more stably chelated biocompatible cyclic form of
Gd-DOTA (Gd-Gadoteric acid) [7].
Although the mainstay of present day diagnostic neu-
rovascular magnetic resonance imaging in everyday clin-
ical practice remains the acquisition of images in signal
space without respect to the quantification of relative con-
trast enhancement [8], magnetic resonance imaging af-
fords the ability to detect contrast-enhanced signal change
in real-time at exquisite resolution as compared to CT or
PET imaging, whereby contrast-enhanced signal change
can be quantified accurately for MRI contrast agents of
appropriate exterior biophysical character [3,9]. Of the
select premier academic centers that offer dynamic
contrast-enhanced MRI-based quantification, these cen-
ters offer bi-compartmental model-based estimates of per-
meability surface area product parameters such as Ktrans
(forward transvascular flow rate per min; permeability
surface area product) [10-12] and Vp (vascular plasma
volume) [12], parameters derived on the basis of the
bi-compartmental modeling of change in normalized
contrast-enhanced plasma signal to that of the change
in normalized contrast-enhanced diseased tissue signal
over time with contrast agents having short blood
half-lives [10,12,13]. Even as model-derived parameters
identify areas of hyperpermeability consistent with patho-
logic hyperpermeability [14] and offer perspective into
therapeutic efficacy for pathologies of known etiology
[15], these parameters such as Ktrans are also normally el-
evated for hyperpermeable healthy tissues [16,17], being
non-specific parameters, making it difficult to discriminate
solid tumor tissue from normally hyperpermeable tissues
such as muscle tissue [18], especially at tumor infiltrating
border zones where the permeability surface area product
values are marginally elevated [16,18].
The poor diagnostic specificity of dynamic contrast-
enhanced MRI-based bi-compartmentally modeled micro-
vascular permeability parameters of small molecule
contrast agent pharmacokineticodynamics [19-23] cannotbe overcome by temporarily increasing the blood half-life
of a small molecule contrast agent by decreasing its renal
filtration fraction [12,24], or alternatively, by increasing
the dose, due to the non-selective extravasation of small
molecule contrast agents of less than 2 nanometers into
healthy tissues with loose macula occludens junctions or
fenestrated endothelial cells [1,2]. The poor diagnostic
cum therapeutic specificity of small molecule contrast
agent pharmacokineticodynamics, however, can be im-
proved by the utilization of biocompatible macromolecu-
lar agents of the dendritic sub-class of larger sizes within
the optimal size range of 7 to 10 nanometers [3,8,25,26]
because even as the per minute forward transvascular flow
rate (Ktrans) from blood plasma into the solid tumor in-
terstitium decreases significantly with increasing contrast
agent molecular size [27,28], the blood plasma half-life of
a contrast agent increases with increasing size, whereby
the contrast agent’s blood plasma half life becomes the
primary determinant of the extensiveness of intratumoral
contrast agent accumulation within solid tumor tissue
[3,8,28,29], which becomes important for the diagnostic
imaging, and importantly, the treatment of solid tumors,
in which small molecule chemotherapeutics do not build
up to effective concentrations [3,30,31].
The current status of the field of translational thera-
nostics is reviewed herein in context of a methodological
discussion of the prototypical quantitative dynamic contrast-
enhanced magnetic resonance imaging-based theranostic
approach for the concomitant diagnosis and non-invasive
treatment of solid tumors, one which has translational po-
tential towards clinical application.
Review
Small molecules and nanoparticles for non- and
semi-quantitative diagnostic imaging
Small molecules with biophysical properties of specific
character have applications for a variety of diagnostic
imaging modalities including dense atom-based for CT
imaging, radioisotope-based for PET imaging, photostable
luminescent atom- or fluorescent organic biomolecule-
based for fluorescent imaging, as well as paramagnetic
atom-based such as Gadolinium-based for magnetic res-
onance imaging [32], however, they possess short blood
plasma half-lives and lack polyvalency, in contrast to their
commensurate macromolecular nanoparticulate-based
forms.
Due to the limitations of small molecule-based diag-
nostic imaging probes, particularly short blood plasma
half-lives and lack polyvalency, over decades, macromol-
ecular and polymeric nanoparticle forms have been
developed, including for quantum dot-based fluorescent
imaging for in vivo applications [33,34], and those of
greater probability for biocompatibility investigated for
clinical imaging, including for PET imaging, which include
Figure 1 Superior sagittal sinus blood plasma Gd concentration
curves over 2 hours following 1 minute bolus intravenous
infusion of Gd-DTPA dendrimer generations G1 through G8
infusions at dose of 0.09 mmol Gd/kg body weight (bw). Blood
plasma concentrations measured via dynamic contrast-enhanced
MRI-based analysis by selection of 5-to-10 voxels in the superior
sagittal sinus (SSS) free from partial volume averaging effects. Gd-G1
(n = 5), Gd-G2 (n = 6), Gd-G3 (n = 6), lowly conjugated (LC) Gd-G4
(n = 4), standard (Std) Gd-G4 (n = 6), Gd-G5 (n = 6), Gd-G6 (n = 5),
Gd-G7 (n = 5) and Gd-G8 (n = 6). Gd-G5 through Gd-G8 dendrimers
rapidly reach and maintain a steady state in blood over 2 hours
(G6, G7 and G8 not shown for clarity). Error bars represent standard
deviation (s.d.) and are shown once every five minutes for clarity.
Adapted from references [3,8,28].
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sess longer blood half-lives at a hydrodynamic molecular
size of approximately 12 nanometers [35], as well as for
diagnostic MRI for the clinical setting, which include: (1)
iron oxide core-based ferromagnetic nanoparticles with
various types of non-covalent dextran-based coatings, be-
ginning in earlier years with interest in the clinical diag-
nostic imaging application of individual particles in the
16 to 35 nanometer size range [36-38], and cumulating in
most recent years towards the clinical development of
very small citrated-dextran coated iron oxide nanoparti-
cles (VSOPs) with an anionic exterior and a molecu-
lar size of approximately 8 nanometers for macrophage
imaging due to the propensity for de-coating and the
uptake of iron oxide cores by cells of the monocycte-
macrophage phagocytic system [39]; and (2) a den-
dritic conjugate of chelated paramagnetic heavy metal
Gadolinium, Gadomer-17, a 17 kDa dendrimer-based
nanoparticle with anionic exterior polyvalency and an im-
proved blood half-life at a molecular size of approximately
3 nanometers, which has been utilized exclusively as a
blood pool contrast agent for perfusion magnetic reson-
ance imaging [40].
In addition to Gadomer-17, other spherical monodis-
perse nanoparticles of the dendrimer sub-class have been
extensively studied in more recent decades, for their appli-
cations as blood pool agents for blood and lymphatic per-
fusion MRI [41-43], as well as for studying microvascular
permeability of hyperpermeable pathology [43-45], which
include the most biocompatible of the imageable dendri-
mer sub-class, those employing cyclic tetracarboxylic acid
DOTA as the chelate for Gadolinium, and demonstrate
biocompatible biophysical character including exterior
functionalization, shape and size, happening to fall within
the molecular size range of 2 nm to 14 nm: This being the
case, however, not much emphasis has been placed on the
following two crucial aspects the first being on the applic-
ability of the imageable dendrimer sub-class for thera-
peutic purposes including those in the optimal size range
for selective transvascular drug delivery of chemotherapy
into hyperpermeable pathologies such as solid tumors,
and the second being, on the applicability of dynamic
contrast-enhanced imaging such as dynamic contrast-
enhanced MRI to non-invasively quantify therapeutic de-
livery into hyperpermeable pathologies voxel-by-voxel,
until most recently [1,3,8,25,26,28,29].
In the few years from 2006 to 2009, it was determined
that imageable dendrimer-based theranostic nanoparti-
cles that possess longer blood plasma half-lives (Figures 1
and 2) achieve effective concentrations in pathologic tis-
sue cells of solid tumors [3,8,28,29], with the optimal
size range for nanoparticles with an anionically neutral-
ized exterior being between 7 and 10 nanometers in
hydrodynamic diameter [3,8,25], which is due to solidtumor blood capillary microvasculature having a physio-
logic upper limit of pore size of approximately 12 nanome-
ters [29], it being more defective than the blood capillary
microvasculature supplying normal healthy tissues [1].
During the course of this experimental studies, the sensi-
tivity of a prototypical translational theranostic approach
for quantifiable dynamic contrast-enhanced imaging-based
concomitant imaging and treatment of solid malignancies
has been validated in over 150 rodent subjects bearing over
250 orthotopic and ectopic malignant gliomas from vol-
umes beginning at 20 mm3 (2–3 mm diameter tumors)
utilizing 7.5 nanometer diameter-sized Gadolinium-DTPA-
dendrimer nanoparticles infused over 1 minute [28,29]
(Figures 3, 4, 5, 6, 7; Table 1) and 9 nanometer diameter-
sized Gadolinium-DTPA-dendrimer-Doxorubicin nanopar-
ticles infused intravenously over 2 minutes [3,8] (Figure 8;
Table 1).
Historical overview on the development of nanoparticles
for therapeutic purposes: From liposomes to dendrimers
Beginning in the 1980s, there has been a virtual explosion
in the field of polymeric science for biological applications
[46-49], which has led to the development of various in-
vestigational macromolecular therapeutics as vehicles for
the delivery of small molecule chemotherapeutics based
Figure 2 Common carotid artery blood plasma Gd concentration curves over approximately 10 hours following 1 minute bolus
intravenous infusion of Gd-DTPA dendrimer generations G5 through G8 at doses of 0.09 mmol Gd/kg body weight (bw). Estimation of
theranostic nanoparticle blood half-lives are determined via DC-E MRI-based analysis by the selection of 5-to-10 voxels free from blood flow
and partial volume averaging effects in a blood vessel of large caliber, the common carotid artery (CCA). Of note, different sets of 5-to10 voxels
selected for each time point with censoring of aberrant T1 values as necessary. Rodent subject n: Gd-G5 (n = 6), Gd-G6 (n = 6), Gd-G7 (n = 5) and
Gd-G8 (n = 5). Adapted from reference [29]. A) Gd-G5, B) Gd-G6, C) Gd-G7, D) Gd-G8.
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[47,50] including to overcome multi-drug resistance [51]
via local sustained release [52], but without emphasis on
the optimal size range or design for biocompatibility in
the biological system in the physiologic state, until re-
cently [1-3,7,8,25,26]. However, it has since then been re-
alized that more attention must be paid to the biophysical
properties of macromolecular therapeutics such as the
purposeful introduction of cationicity to the exterior of
sub-optimally sized nanoparticles in order to improve
their permeation across the blood-tumor barrier and dif-
fusion through the tumor interstitium [53,54], which re-
sults in significant non-selective toxicity to the biological
system in the physiologic state [2,3,25,26]. Of the selected
subset of these macromolecular drug carriers that have
been tested in the clinical setting for therapeutic ap-
plications, these include liposomes in the 100 to 200Figure 3 T1-weighted dynamic contrast-enhanced MRI voxel-by-voxel
within large orthotopic RG-2 malignant brain tumors. The volume, in m
Gd-G3, 94; lowly conjugated (LC) Gd-G4, 162; standard Gd-G4, 200; Gd
Gd-dendrimer generations administered intravenously over 1 minute a
0 mM [Gd] to 0.1 mM [Gd]. Adapted from references [3,8,28].nanometer size range [55,56]; it is sufficient to re-
iterate that for non-pegylated liposomal doxorubicin
(Myocet/Doxil), there is the rapid uptake of the non-pegylated
forms (Myocet/Doxil) by the monocycte-macrophage
phagocytic and reticuloendothelial systems, which results
in only micormolar concentrations in blood plasma [57],
and that for the pegylated forms (Caelyx) with longer cir-
culatory half lives than that of the non-pegylated form
[57], there is a widespread myoinflammatory response
manifesting as different grades of palmar-plantar erythro-
dysesthesia (hand-foot syndrome) [58], which is likely a
form of microvascular inflammatory necrosis (author obser-
vation) due to the continuous slow release of low concen-
trations of doxorubicin, a cationic lipophile anthracycline
antibiotic of hydro-lipophilic character, which is directly
toxic to cellular membranes, particularly to capillary wall
endothelial cell membranes: Importantly, in the cases ofGd concentration maps of Gd-dendrimer distribution over time
m3, for each large orthotopic RG-2 glioma: Gd-G1, 104; Gd-G2, 94;
-G5, 230; Gd-G6, 201; Gd-G7, 170; and Gd-G8, 289. Respective
t a Gd dose of 0.09 mmol Gd/kg animal body weight. Scale from
Figure 4 T1-weighted dynamic contrast-enhanced MRI Gd voxel-by-voxel Gd concentration maps of Gd-dendrimer distribution over
time within small orthotopic RG-2 malignant brain tumors. The volume, in mm3, for each small orthotopic RG-2 glioma: Gd-G1, 27; Gd-G2,
28; Gd-G3, 19; lowly conjugated (LC) Gd-G4, 24; standard Gd-G4, 17; Gd-G5, 18; Gd-G6, 22; Gd-G7, 24; and Gd-G8, 107. Respective Gd-dendrimer
generations administered intravenously over 1 minute at a Gd dose of 0.09 mmol Gd/kg animal body weight. Scale from 0 mM [Gd] to 0.1 mM
[Gd]. Adapted from references [3,8,28].
Sarin Neurovascular Imaging  (2015) 1:3 Page 5 of 16both, there is the release of small molecule free drug is
into systemic circulation, whereby the free drug itself
does not accumulate to effective concentrations within
solid tumor tissue itself, due to a upper limit of pore
size of approximately 12 nanometers in the hyper-
permeable blood capillaries supplying solid tumor tis-
sue [28,29].
In more recent years, there has been exquisite interest
in the development of various kinds of biocompatible
nanoparticles for therapeutic purposes that remain in the
optimal size range of 7 to 10 nanometers upon functiona-
lization, but which has been tempered by the realization
that it is difficult to engineer such biocompatibly-sized
nanoparticles having covalently-bound stable biocom-
patible exteriors without toxic metal cores that do not
biodegrade. Examples of nanoparticles in the optimal
size range that fail to meet this criterion include the
8 nanometer-sized very small Iron Oxide core nano-
particles with a non-covalently-bound dextran organic
biomolecule coating (VSOP-C184) [59], as well as the
5 to 10 nanometer-sized Cadmium-Tellurium or Cesium-
Selenium core quantum dots, which have non-biocompatible
metal cores and require non-covalent capping with Zinc-
Sulfur and coated with organic biomolecules that them-
selves may or may not be biocompatible [33].
In contrast to other nanoparticles within the optimal
size range, dendrimers are unique nanoparticles [8,25],
as dendrimers are spherical nanoparticles with optimal
terminal branch surface area-to-volume ratios and no
significant increase in volume upon hydration, with the
naked, non-functionalized, dendrimer being a repeating
biocompatible monomeric units with terminal branchesincreasing exponentially by 2x units doubling for each
successive full-generation, beginning with reference to
the dendritic core, the zero generation dendrimer (G0)
having 4 terminal branches (x = 2), with the 1st generation
dendrimer (G1: 1.4 kDa; 1.9 nm diameter [Dendritic
Nanotechnologies, Inc]) having 8 terminal branches (x = 4)
and the 5th generation dendrimer (G5: 29 kDa; Diameter
est at 5.5 nm [60]) having 128 terminal branches (x = 7)
(NH3+), for example, whereas half-generation dendri-
mers (G1.5, G2.5 etc.) have intermediate numbers of
terminal branches (COO-, OH) [61,62]. Even though
dendrimer-based nanoparticles have been extensively
researched in the past for their potential to be effective at
chemotherapeutic drug delivery into solid tumors [63-69],
including for folate receptor-targeted chemotherapeu-
tic drug delivery [70-74], these investigations have
been without emphasis on the optimal size range of 7
to 10 nanometers, the optimal density or the optimal
exterior functionalization for effective, passively selective
transvascular delivery, without risk of systemic toxicity,
biophysical aspects that have important translational im-
plications [1-3,7,8,25,26] (Table 1).
Optimally sized and designed MRI imageable
functionalized dendrimers for theranostic purposes
Nanoparticles of the dendrimer class are monodisperse
[60], and functionalized MRI imageable dendrimers with
anionically neutralized exteriors maintain their monodis-
persity within a very narrow size distribution in their re-
spective generation as determined by transmission electron
microscopy [28,29,75], whereby the higher generation
dendrimers functionalized with paramagnetic heavy metal
Figure 5 Orthotopic RG-2 malignant glioma tumor tissue Gd concentration curves over 2 hours upon 1 minute bolus intravenous
infusion of Gd-DTPA dendrimer generations at dose of 0.09 mmol Gd/kg bw and infusion of Gd-DTPA dendrimer-linker-Rhodamine
dendrimer generations at dose of 0.06 mmol Gd/kg body weight (bw). RG-2 glioma tumor tissue concentration curves are weighted with
respect to total tumor volume (large anterior and small posterior contralateral) with error bars representing standard deviation (s.d.) and
shown once every five minutes for clarity. Tumor N per group: Gd-G1 (n = 10), Gd-G2 (n = 12), Gd-G3 (n = 12), lowly conjugated (LC) Gd-G4
(n = 8), standard (Std) Gd-G4 (n = 12), Gd-G5 (n = 12), Gd-G6 (n = 10), Gd-G7 (n = 10) and Gd-G8 (n = 12); Gd-G5-linker-Rhodamine (n = 10) and
Gd-G8-linker-Rhodamine (n = 4). Of note, Normal brain tissue curves concentration curves for Gd-G1 and Gd-G5 dendrimer groups are
shown of 9 mm3 brain volumes, which reflect intravascular blood concentration of Gd-dendrimer Gd in the absence of any extra-vascular
extravasation of the respective Gd-dendrimer generations (other Gd-dendrimer generations not shown for clarity). Based on the tumor tissue
extravasation concentration curves of the non-cationotoxic Gd-dendrimers (non-Rhodamine functionalized), the upper limit of pore size of the
blood-tumor barrier is between the size of the Gd-G7 dendrimers (~11 nm) and that of the Gd-G8 dendrimers (~13 nm). Of note, Gd-G5
dendrimer-linker-Rhodamine and Gd-G8 dendrimer-linker-Rhodamine tumor tissue concentration curves accumulate over time in tumor
tissue at 2/3rd the dose of the non-Rhodamine Gd-dendrimers, the Gd-G5 dendrimer-linker-Rhodamine dendrimer to a significant extent, which is due to
cationic toxicity of the blood-tumor barrier, which is also the case of the Gd-G8 dendrimer-linker-Rhodamine (Curve not shown: The cationotoxic extravasation
across the normal blood brain-barrier and accumulation in normal brain tissue, which reflects cationic toxicity to the normal healthy blood–brain barrier)
Adapted from references [3,8,28]. A) Gd-G1, B) Gd-G2, C) Gd-G3, D) LC Gd-G4, E) Std Gd-G4, F) Gd-G5, G) Gd-G6, H) Gd-G7, I) Gd-G8.
Sarin Neurovascular Imaging  (2015) 1:3 Page 6 of 16chelates on the exterior remain within the 7 to 10 nano-
meter size range following functionalization, which is
the case for the range of Gd-DTPA-G5 dendrimer (80–
85 kDa; Diameter est at 7.5 nm) [3,8,28,29,76] (Table 1). In
the case of the Gd-DTPA-G5 dendrimer-linker-Doxorubicin
(85 kDa), its diameter as measured by dynamic light scat-
tering in serum albumin protein-free solution, is at 9
nanometers [3] (Table 1), due to the linker attachment ofDoxorubicin to the exterior, which protrudes ~1.5 nano-
meters above the nanoparticles surface.
In the case of MRI imageable functionalized dendri-
mers, it is notable that there is a significant increase in the
density of nanoparticle molecular weight upon the conju-
gation of chelated paramagnetic heavy metal Gadolinium
(0.157 kDa) either by DTPA (0.393 kDa) or by DOTA
(0.404 kDa) as when ~50% of the terminal amines of
Figure 6 T2–weighted anatomical MRI images and T1-weighted dynamic contrast-enhanced MRI voxel-by-voxel Gd concentration
maps of higher generation Gd-dendrimer distribution over approximately 3 hours within orthotopic and ectopic RG-2 malignant
solid tumors. The volume, in mm3, for each orthotopic and ectopic RG-2 glioma: First row, Gd-G5; 45 mm3 (brain), 113 mm3 (peripheral); Second
row, Gd-G6; 97 mm3 (brain), 184 mm3 (peripheral); Third row, Gd-G7; 53 mm3 (brain), 135 mm3 (peripheral); Fourth row, Gd-G8; 50 mm3 (brain);
163 mm3 (peripheral). Respective Gd-dendrimer generations administered intravenously over 1 minute at a Gd dose of 0.09 mmol Gd/kg animal
body weight. Scale from 0.00 mM [Gd] to 0.15 mM [Gd]. Adapted from references [8,29].
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conjugated the cationic exterior of the naked polyamidoa-
mine dendrimer (Table 1), it is anionically neutralized due
to the presence of 2- charges of the Gd-DTPA/DOTA
chelates protruding on the exterior of the MRI imageable
functionalized dendrimer. Furthermore, the Gd-DTPA
functionalized molecular weight is ~2.6-fold that of the
naked dendrimer weight (Table 1), and importantly, the
functionalized dendrimer size is only ~1.5 nanometers lar-
ger than that of the naked dendrimer (Table 1), which is
superior to method of exterior pegylation to increase mo-
lecular weight in which case the overall size of the mol-
ecule increases disproportionately to greater than that of
the 7 to 10 nanometer size range. Therefore, imageableFigure 7 Orthotopic and ectopic RG-2 malignant glioma tumor tissue Gd c
infusion of Gd-DTPA dendrimer generations G5 through G8 at doses of 0.0
solid tumor tissue concentration curves of intra-cranial caudate nucleus tumors (av
tumors (average volume ~150 mm3) grown in the same rodent subjects. The Gd
represent whole tumor average Gd concentrations determined on the basis of co
volumes and not voxel-by-voxel. Shown is the best fit curve by least squares mini
(n = 5); Ectopic n: Gd-G5 (n = 6), Gd-G6 (n= 6), Gd-G7 (n = 5) and Gd-G8 (n = 5). A
Orthotopic RG-2 tumor, C) Gd-G7 Orthotopic RG-2 tumor, D) Gd-G8 Orthotopic RG
Gd-G7 Ectopic RG-2 tumor, H) Gd-G8 Ectopic RG-2 tumor.heavy metal chelate-based functionalization helps main-
tain a compact configuration that becomes important for
optimally prolonged blood plasma half life as the densely
chelated compact nanoparticle does not proteolytically de-
grade as rapidly in systemic circulation, which has an
anionically neutralized exterior.
The other important consideration with regards to the
optimal overall design of MRI imageable functionalized
theranostic dendrimer nanoparticles within the 7 to 10
nanometer size range towards clinical application is the
biophysical character of the functionalized nanoparticle
exterior upon outermost exterior covalent functionaliza-
tion of small molecule probes with inherent lipophilic
cationicity such as fluorescent dye, linker-Rhodamine oroncentration cures over 10 hours following 1 minute bolus intravenous
9 mmol Gd/kg body weight (bw). Orthotopic and ectopic RG-2 malignant
erage volume ~100 mm3) and contralateral extra-cranial temporalis muscle
concentration values of free moving rodent subjects in-between scans
-registered tumor slice volume region-of-interest values for entire tumor
mization. Orthotopic n: Gd-G5 (n= 6), Gd-G6 (n = 6), Gd-G7 (n= 5) and Gd-G8
dapted from reference [8,29]. A) Gd-G5 Orthotopic RG-2 tumor, B) Gd-G6
-2 tumor, E) Gd-G5 Ectopic RG-2 tumor, F) Gd-G6 Ectopic RG-2 tumor, G)





























Gt-dtpa-G1 8 1.43 1.9 67.1 5.63 9.8
Gt-dtpa-G2 16 3.26 2.6 65.9 11.2 10.1
Gt-dtpa-G3 32 6.91 3.6 47.7 18.6 10.4
Low Gd-dtpa-G4 64 14.2 4.4 29.8 24.4 7.8
Std Gd-dtpa-G4 64 14.2 5.7 47.5 39.8 12.2
Gd-dtpa-G5 128 28.8 est 5.5 47.2 79.8 est 7.5 109
Theranostic G5 128 28.8 est 5.5 48.1 7.8 85.0 n/a 9 10.1
Gd-dtpa-G6 256 58.0 6.9 39.9 133 est 10 10.6
Gd-dtpa-G7 512 116 8.0 50 330^ 11 10.3
Gd-dtpa-G8 1024 233 10.3 37.8 597^ 13 9.4
Blank = not available.
G = Dendrimer Genaration.
& = Combination of outside data from Dynamic light scattering and TEM findings of Ref 60 and Dendritic Nanotechnologies,Inc.
~1 = Based on (MALDI TOF Functionalized Dendrimer Weight - Naked Dendrimer Weight) / 725; Gd-DTPA unit Weight = 725 Daltons.
Doxorubicin (544 Da) + Linker Weight (278 Da) = 822 Daltons (8 Doxorubicin per Funtionalized Dendrimer).
* = Dynamic light scattering measurement for Gd-DTPA-dendrimer-Hydrazone LINKER-Doxorubicin; Otherwise estimated or measured per ADF TEM.
^ = Measured by ADF TEM; Otherwise measured by MADLI TOF spectroscopy.
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is a form of hydro-lipophilicity [7]: Nanoparticles with cat-
ionic exteriors are particularly toxic to cellular membranes,
due to the presence of multivalent exterior cationicity pro-
truding outwards from the nanoparticle (Figure 5, Panels F
and I; Figure 8), which, when present on the exterior of cir-
culating nanoparticles cause systemic blood-endothelial
cell capillary barrier damage as evidenced by non-selective
contrast enhancement of the normal blood–brain barrier
on dynamic contrast-enhanced MRI [3,8]; this is the case
for the prototype of a MRI imageable theranostic dendri-
mer, whose biophysical character is altered due to the
introduction of cationic lipophilicity onto its surface that
protrudes above the biocompatible anionicity of its pre-
existing chelated exterior [2,3,7,8], which results in non-
selective systemic toxicity to normal healthy microvascular
barriers including to the normal blood–brain barrier
[3,8] (Figure 8) and is the likely reason for the observedFigure 8 T2-weighted anatomic MRI scan image of an orthotopic RG-2 m
MRI voxel-by-voxel Gd concentration maps at baseline and at 60 minut
highlights non-selective contrast enhancement in normal brain tissue. The Gd
a Gd dose of 0.09 mmol Gd/kg animal body weight, which is equivalent to a
to 0.2 mM [Gd]. Adapted from reference [3,8].dose-limiting systemic toxicities in experimental stud-
ies with dendrimer-based therapeutics with targeting
or therapeutic moieties of cationic lipophilic character
on the exterior [72,77-79].
It can therefore be surmised that dendrimers are truly
unique nanoparticles in that they possess the inherent
inner architecture to proteolytically biodegrade along with
the potential to be functionalized on the exterior via cova-
lent modifications whereby their biophysical properties
can be fine-tuned for: (1) Optimizing size to within the 7
to 10 nanometer range [1-3,8,25,26], which is optimal for
passively selective transvascular delivery into hyperperme-
able pathologies such as solid tumors but not to healthy
tissues [2] (Figures 3 through 7; Table 1); (2) Optimizing
density by covalent attachment of strongly chelated
imageable heavy metals [3,8,25,26], which maintains their
compactness and slows proteolytic degradation while in
systemic blood circulation [2,7] (Figures 1 and 2); and (3)alignant brain tumor and T1-weighted dynamic contrast-enhanced
es following Gd-G5-doxorubicin dendrimer infusion. Red arrow
-G5-doxorubicin dendrimer administered intravenously over 2 minutes at
doxorubicin dose of 8 mg/kg animal body weight. Scale from 0 mM [Gd]
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droxylated anionicity via covalent attachment [3,8,25,26],
which makes them biocompatible in blood circulation for
prolonged duration and maximizes their blood half-life
while rendering them free from biophysical interactions
with circulatory or interstitial proteins such as serum al-
bumins [2,7] (Figures 1 and 2).
Quantitative dynamic contrast-enhanced imaging for
theranostic purpose
In the case of contrast-enhanced CT- and PET-based im-
aging employing purely hydrophilic contrast agents there
is a linear correlation between the observed contrast en-
hancement signal and concentration of the contrast agent
in tissue as these modalities detect either the opacity or
the radioopacity, respectively, of the contrast agent. This,
however, is not the case for contrast-enhanced MRI where
the observed contrast enhancement signal is a function of
several factors that must be taken into consideration the
concentration of the agent infused and the temperature,
the imaging sequence repletion and echo times (TR, TE)
and the amount of the decrease in the longitudinal relax-
ation time (T1) and increase in longitudinal relaxation rate
(R1, 1/ms) of water molecule protons resulting per unit
concentration of the contrast agent (r, ms−1/mM) in con-
text of the Larmor precession frequency (ω), which is a
product of the gyromagnetic ratio (g) of a charged protons
of water molecules and the strength of the magnetic field
(B0) [80]. In magnetic resonance imaging, tissue signal re-
sults when energy is applied (E) when a radiofrequency
pulse is applied in a static magnetic field to perturb tissue
water molecule protons (nuclear spin with 1+ charge)
already precessing at the Larmor frequency in alignment
with the magnetic field (M vector: M0, Equilibrium
Magnetization), with the rate of re-alignment being de-
tected at the sequence pre-determined time of detection
(Echo time: TE) by a receiving coil. Repetitive firing of
radiofrequency pulses (Repetition time: TR) of a pre-
determined strength (flip angle α) results in repetitive de-
viations from z-axis (Mz longitudinal axis vector) towards
the x-y plane (Mx-My plane vectors) that are measured
during the return of the longitudinal magnetization (longi-
tudinal re-growth time: T1 relaxation time), which is the
basis for the T1-weighted MRI image generation following
Fourier transforms of the detected signal, the T1 signal.
In dynamic contrast-enhanced imaging, a small mol-
ecule or macromolecular contrast agent is infused while
images are acquired sequentially in real-time, these be-
ing radiographic images in the case of dynamic CT and
PET, and resonance images in the case of dynamic MRI,
making it possible to observe the difference in the base-
line pre-contrast signal to that of the contrast-enhanced
signal (normalized signal), which, in the case of dynamic
contrast-enhanced MRI can be further quantified interms of contrast agent concentration by applying the
dual-flip angle methodology and the pre-determined molar
relaxivity of a hydrophilic contrast agent (r: ms−1/mM),
upon which concentration curves and maps can be gener-
ated voxel-by-voxel for the duration of imaging session
(All figures except Figure 7). In the case of purely hydro-
philic small molecule contrast agents such as Gd-DTPA/
DOTA (0.73 kDa; 0.8 nm), which has an overall charge
of 2-, a temporal resolution of 30 minutes or less is suffi-
cient to assess the pathologic tissue’s pharmacokineti-
codynamic curve profile; whereas, in the case of small
molecule contrast agents of part hydrophilic character such
as serum albumin-associating contrast agent Gadofosveset
(~0.91 kDa), which is part neutral and part anionically
charged and remains in the blood pool for increased dur-
ation [81], as well as in the case of hydrophilic macromol-
ecular contrast and theranostic agents greater than 4
nanometers in diameter, a temporal resolution of upwards
of 2 hours is often necessary to properly assess the patho-
logic tissue’s pharmacokineticodynamic curve profile.
The visualized contrast concentration results from the
combination of contrast-enhanced intra-vascular signal,
and in the subset of tissues supplied by blood capillaries
permeable to the contrast agent, from the pooling of
contrast agent within tissue interstitium followed by
intracellular uptake [12], processes that can be separated
out by visual inspection of the pathologic tissue’s phar-
macokineticodynamic curve profile, in context of the
blood plasma’s pharmacokineticodynamic curve pro-
file, for the theranostic dendrimer, with the potential
for increased diagnostic imaging sensitivity upon the
assessment of the tissue response pharmacokineticody-
namic curve profiles for a couple or series of image-
able dendrimer-based contrast agents of various sizes
(generations).
The sensitivity of dynamic contrast MRI-based detec-
tion of hyperpermeable pathologic tissue utilizing a
purely hydrophilic contrast agent is primarily a function
of, one, hydrophilic contrast agent size, which increases
its blood half-life of the agent, and two, the efficiency by
which it relaxes water protons per molar concentration,
which increases with polyvalency and then plateaus off.
The short blood plasma half-lives of hydrophilic small
molecule contrast agents and their lower efficiency to
relax water protons (low molar relaxivity) are limitations
that can be overcome by decreasing renal filtration frac-
tion [12] or increasing the dose of the contrast agent,
both of which increase agent blood plasma half-life, but
which also increase the risk for non-selective systemic
toxicity of small molecule contrast agents of less than 2
nanometers, which can extravasate appreciably across
healthy microvascular barriers, and in the case of small
molecule chemotherapy, often becomes the treatment
dose-limiting toxicity [1,2].
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the mid-sized higher generation dendrimer-based thera-
nostic agents possess longer blood half lives and those
with neutralized-to-anionic exteriors within the optimal
size range of 7 to 10 nanometers are passively selective for
solid tumor foci and provide exquisite contrast enhance-
ment of solid tumor foci over several hours as they accu-
mulate over time to 0.20 mM average maximum with
respect to Gadolinium concentration in peripheral solid
tumors and to 0.15 mM average maximum with respect
to Gadolinium concentration in intracranial solid tumors
[8,29] at significantly lower doses of administration than
in their free small molecule form of Gd-DTPA, whereby,
the Gd-G5 DTPA-dendrimer (est at 7.5 nm) provides
superior intra-tumoral accumulation and prolonged con-
trast enhancement upon intravenous administration at
0.09 mmol Gd/kg body weight over 1 minute [3,8,28,29]
(Figure 7), as compared to Gd-DTPA administered at the
0.30 mmol Gd/kg body weight dose over one minute
(triple dose Gd-DTPA), which provides fleeting contrast
enhancement [12]. Furthermore, the dosing of Gd-G5
DTPA/DOTA-dendrimers is on the order of 80–100 mg/
kg body weight per dose [3,8] and 1/7th to 1/2 of that
of hydrophilic small molecule contrast agents such as
Gd-DTPA/DOTA administered at triple dose, for which
reason the probability for any systemic hypersensitivity
associated with MRI imageable dendrimers functional-
ized biocompatibly with small molecule therapeutics
is likely low.
On the applicability of in vitro determinations of
theranostic dendrimer molar relaxivity to the in vivo state
The molar relaxivity of the contrast agent, r (ms−1/mM),
which is the amount of increase in the relaxation rate of
water protons per unit concentration of agent, has been
extensively studied in vitro for a variety of paramagnetic
contrast agents at various field strengths (T) at various
temperatures (°C) including dendrimer-based, ie [82,83],
which has been from the basic science perspective of the
physical sciences, with the objective of selecting MRI
contrast agents with improved proton longitudinal relax-
ation efficiency per millimolar concentration of the para-
magnetic contrast agent (r1, .here simply r). Based on
these in vitro studies, it has been determined that para-
magnetic contrast agent molar relaxivity increases with
increasing exterior polyvalency of chelated Gadolinium
to a point after which it plateaus, whereby the Gd-chelated
high-generation dendrimers (Gd-DTPA/DOTA G5 dendri-
mers and higher) have a plateaued r of 20 ms−1/mM at
1.5 T @ 20° [83] and of ~25 ms−1/mM at 1.5 T @ 37°
[82,83], and a plateaued r of between 10 and 12 ms−1/mM
at 3.0 T @ 37° [3,8,28,29,83], in contrast to monovalent
Gd-DTPA, which has a r of ~4 ms−1/mM at 1.5 T @ 37°
[81] and a r of 3.8 ms−1/mM at 3.0 T @ 37° [12]. Thesefindings are analogous to those noted with respect to the
adsorption of several small molecule contrast agents onto
nanoporous surfaces [84].
It is difficult, however, to determine the molar relaxiv-
ity in vivo as it requires accurate determinations of the
actual tissue concentration of the contrast agent at the
time of the acquired image, which historically typically
has been Gd-DTPA, a hydrophilic contrast agent with a
short blood half-life that readily diffuses out of the tissue
interstitium [85,86], unlike, for example, 14C-alpha ami-
noisobutyric acid (14C-AIB) [7,11], a 14C-modified syn-
thetic amino acid that readily localizes intracellularly [7].
In the case of macromoleculars, if the molar relaxivity of
a theranostic dendrimer can be determined accurately
in vitro, then the in vitro approach would methodologic-
ally useful for application across laboratories and centers
due to the ease of reproducibility.
From the translational science perspective, it is im-
portant to understand the salient biophysical interac-
tions that alter a theranostic agent’s molar relaxivity in
the physiologic state in vivo. An important observation
in this respect is that for a contrast agent with part lipo-
philic character, the molar relaxivity is much greater in
the presence of protein serum albumin, which is the case
of Gadofosveset (Vasovist), a Gd-DTPA-based contrast
agent of anionic hydro-lipophilic character with serum
albumin-associating ability [7] that has a r of 28 ms−1/
mM at 1.5 T @ 37° [87], in contrast to Gd-DTPA that
is of pure hydrophilic character [7] that has a r of
3.8 ms−1/mM at 3.0 T @ 37° [12], irrespective of the
presence of protein. This observation that there is in-
creased contrast agent molar relaxivity in the presence of
associative serum albumins, blood serum and interstitial,
is consistent with transiently acquired non-covalent asso-
ciative polyvalency in the presence of serum albumins,
and becomes particularly relevant to take into consider-
ation when designing theranostic dendrimers, as exterior
functionalization with moieties such as fluorescent
dyes or chemotherapeutics of lipophilic character. In the
case of functionalized theranostic dendrimers or other
such nanoparticles where foreseeable protein interactions
in vivo not considered a priori, the dynamic contrast-
enhanced MRI-based Gd concentration maps gener-
ated on the basis of molar relaxivity determinations
of theranostic nanoparticles made in vitro in phos-
phate buffered saline (PBS) would display greater Gd
concentration than actually present intratumorally in
the form of Gd-DTPA/DOTA-dendrimer; in the case of
theranostic nanoparticles without this exterior introduc-
tion of lipophilicity and maintained post-functionalization
protruding exterior hydrophilicity (i.e. Gd-DTPA-
dendrimers), this effect modifier is unlikely to be
much of a factor in introducing inaccuracy into the
methodology [7].
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a functionalized theranostic agent’s in vivo molar relaxiv-
ity is only equivalent to it’s in vivo molar relaxivity if the
theranostic agent does not associate with serum proteins:
This is only the case for purely hydrophilic theranostic
agents of anionically neutralized stable exteriors with
covalently bound chelates [2,7]. For theranostic probes
without this exterior biophysical character of anionically
neutralized exteriors, adjustments would need to be made,
and furthermore, the reliability of these adjustments for
accurate quantification of theranostic agent concentration
in vivo must be questioned.
Methodology for the in vitro determination of
theranostic dendrimer molar relaxivity for in vivo
application
Purely hydrophilic theranostic agents of anionically neu-
tralized stable exteriors with covalently bound chelates,
the molar relaxivity can be measured accurately in vitro
in phosphate buffered saline at body temperature (37°C)
in the 3 T magnet solenoid coil utilized for the in vivo
dynamic contrast-enhanced imaging [3,8,12,28,29], which
approximates that of the in vivo state in the absence
of any appreciable protein binding, as is the case for
pure hydrophiles [7,88]. Theranostic dendrimer nano-
particle molar relaxivity is determined by T1-weighted
Spin-Echo (SE) MRI methodology utilizing different
repetition times (SE TR; ie 100, 300, 600 and 1200 ms)
and a constant echo time (SE TE; ie 10 ms) for a series
of diluted Gd-DTPA-dendrimer PBS solutions with respect
to Gadolinium concentration (0, 0.25, 0.50, 0.75, 1.0 and
2.0 mM) for the determination of the normalized longitudinal
relativity rates (1/T1) for each Gadolinium concentration
via column (m: TR)-by-row (n: Gadolinium concentration)
matrix comparisons of contrast-enhanced T1 signal to
non-contrast PBS T1 signal by applying Equation 1:









The Gd-DTPA/DOTA-dendrimer theranostic nanopar-
ticle molar relaxivity rate is calculated by linear regession
of normalized longitudinal relativity rates (1/T1) plotted
on the y-axis versus Gd-DTPA-dendrimer Gadolinium
concentration (0, 0.25, 0.50, 0.75, 1.0 and 2.0 mM) plotted
on the x-axis, with the slope of this line being the thera-
nostic dendrimer nanoparticle molar relaxivity, r (ms−1/






Since the increase in measured signal intensity is not lin-
ear across SE repetition times particularly at concentrationsgreater than 0.50 mM Gadolinium, imaging of concentra-
tion dilutions at multiple repetition times assures accuracy
of the in vitro molar relaxivity determination for the entire
range of physiologically relevant concentrations of Gado-
linium to be encountered in blood plasma (~1.2 mM) and
tumor tissue (~0.1-0.2 mM). The tissue specificity of the
spin-echo-based in vitro molar relaxivity determination
methodology can be further improved by narrowing the
range of in vitro theranostic dendrimer dilutions to that of
the Gadolinium concentrations to be encountered specif-
ically in either blood plasma, or in tumor tissue.
The steps for post-processing of the raw Spin Echo
molar relaxivity data include molar relaxivity calculations
that are performed directly in Matlab following conversion
of .Par scan header parameter information into .Brik file
signal data and capturing of ROI mask .Brik file signal
data into a single Matlab .1D files and then executing
UNIX-based custom scripts to batch process, by calling
onto the Matlab suite to apply Matlab-based scripts (.m).
Methodology for the dynamic contrast-enhanced
magnetic resonance imaging of theranostic dendrimer
nanoparticles
In the case of dynamic contrast-enhanced magnetic reson-
ance imaging, the most applicable methodology for dy-
namic contrast-enhanced MRI is the T1-weighted SPoiled
Gradient Recall Echo (SPGR, GRE; Fast-Field Echo [FFE])
dual-flip angle methodology for quantification of signal
intensity in concentration space, which permits the rapid
acquisition of high-resolution dynamic scan images over
time [80]. Furthermore, SPGR T1-weighted imaging se-
quences generate homogenous signal for small field-of-
views without tissue interface artifact and are particularly
applicable for the treatment cum imaging while delineat-
ing discrete volumes of hyperpermeable pathology and
pathology-normal tissue interfaces (ie rodent, primate
and human tumor foci) following the intravenous bolus
administration of paramagnetic theranostic nanoparticles
with long blood half lives and low serum albumin-
association potential such as the Gd-DTPA/DOTA-
dendrimers in the optimal size range of 7 to 10 nanometers.
Being that the maximum achievable magnetization for
a radiofrequency pulse is governed by the duration and
intensity of the radiofrequency pulse and that a pulse of
greater strength yields a larger flip angle α, while the T1-
weighted signal decays at a constant rate irrespective of
applied radiofrequency energy, the following relationship
holds the T1-weighted signal, S, in case of the dual flip-
angle methodology, as defined per Equations 3 and 4:
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sinα1
¼ S2 1−E cosα2ð Þ
sinα2
ð4Þ
where α1 = low-flip angle for 1stflip radiofrequency pulse
signal S1 (ie 3 deg).
Where α2 = high=flip angle for 2ndflip radiofrequency
pulse signal S2 (ie 12 deg).
Since the objective is to generate the normalized relative
signal pre-contrast map for quantification of contrast agent
concentration upon α2 high-flip angle dynamic contrast-
enhanced image acquisition, Equation 4 can be solved for
the ESα2pre/Sα1pre value to yield Equation 5:
E sα2pre=sα1pre ¼ S2 sinα1−S1 sinα2S2 cosα2 sinα1−S1 cosα1 sinα2
ð5Þ
The ESα2pre/Sα1pre value is applied to generate the
relative normalized T1-weighted signal intensity map as
defined per Equation 6:
Srelative
0 tð Þ ¼ S tð Þ=S1@α1 ¼
1−E tð Þ







The expression for the decay in electromagnetic energy
over time over successive pulses in context of contrast
agent-induced tissue contrast enhancement is:
ET1post=pre tð Þ ¼ exp −
TR
T 1post=pre tð Þ
 





Knowledge of the relationships defined by Equations 5,
6 and 7 form the basis for quantification of the amount of
contrast enhancement at α2 for each image acquisition
in concentration space with respect to the imaging agent
moiety (i.e. Gadolinium) or even the agent itself (i.e. Gd-
DTPA-dendrimer), where r is the molar relaxivity in msec−1
time/mM contrast agent concentration measured in vitro
(Equations 1 and 2) and substituted into Equation 8,
whereby the dynamic MRI concentration map is generated
voxel-by-voxel (0.5 mm by 0.3 mm by 0.3 mm) per tissue
volume slice with respect to contrast agent Gadolinium con-
centration to quantify the change in the concentration of
theranostic dendrimer nanoparticle in the tissue of interest
such as blood plasma and solid tumor over time (All figures
except Figure 7), which can also be made for a region-of-
interest considered as one large voxel, where applicable
(Figure 7). The quantitative dynamic MRI theranostic agent
Gd concentration over time is defined as per Equation 8:DynamicMRI C tð Þmap ¼ 1
rTR
1n
ESα2pre=Sα1pre½S0 tð Þ 1−ESα2pre

S0 tð Þ 1−ESα2pre=Sα1
For calculation of the change in the agent concentration
over time in blood plasma, a few representative voxels are
chosen from a small vein or artery, of sufficient diameter
including the superior sagittal [venous] sinus (Figure 1)
and the common carotid artery (Figure 2): The systemic
healthy tissue extraction per circulatory pass in insignifi-
cant for optimally sized imageable nanoparticles while the
blood transit time from arterial-to-venous circulation is
1/4th of that of the temporal resolution (20 s per slice)
resulting in similar concentrations in either circulation,
whereby it is appropriate to utilize SSS voxels for deter-
mining blood concentration of the theranostic agent. It is
bit more difficult to select artifact-free voxels in the com-
mon carotid artery due to flow artifact on slices that are in
the periphery of the field-of-view and requires some train-
ing. The tumor tissue fractional blood plasma volume
(Vp) is relatively insignificant and on the order of 3-5%
and not necessary to factor in for determination of con-
centrations of interstitial and cellular solid tumor tissue
contrast agent concentrations.The concentration of the
theranostic dendrimer nanoparticle in the plasma of
blood requires knowledge of the red blood cell frac-
tion (Hematocrit: Hct), which is typically around 0.46
in the case of blood-less microsurgery and defined as
per Equation 9:
Cp ¼ Cb1−Hct ð9Þ
Native acquired dynamic contrast-enhanced MRI signal data
are analyzed using the Analysis of Functional NeuroImages
(AFNI; http://afni.nimh.nih.gov/) [89] software suite programs
such as 3Dvolreg for motion correction, 3Dautobox for
cropping, and 3Droistats and 3Dmaskave for extracting
parameters for manually-drawn ROI masks in the UNIX
programming environment, called-on by simple com-
mands and in custom-made UNIX scripts (.csh). For the
dynamic contrast-enhanced MRI signal data, the dual flip
angle dynamic contrast-enhanced MRI signal data files
(.Par header information and .Rec files) are extracted and
converted to native AFNI format signal data (.Head .Brik
files), with the entire hi-flip dynamic signal data set mo-
tion corrected, after which the low flip and high flip signal
data are co-registered, each dynamic high flip angle vol-
ume over time to its corresponding low flip angle volume
signal data of a single time point, with alignments made
by Fourier interpolation. The signal space to concentra-
tion space data conversion is then performed by the
application of the custom-made UNIX scripts applying
Equations 3 through 9.=Sα1preÞ cosα2−ESα2pre=Sα1pre cosα2−1

pre
þ ESα2pre=Sα1pre cosα2−1 ð8Þ
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contrast-enhanced magnetic resonance imaging
Two different variations of the SPoiled Gradient Recall
Echo (SPGR) dual-flip methodology have been applied
for in vivo dynamic contrast-enhanced MRI for the quan-
titative theranostic imaging of functionalized dendrimer
nanoparticle accumulation over time into the interstitium
of rat glioma-2 (RG-2) malignant gliomas grown orthoto-
pically and ectopically [3,8,11,12,28,29], which are syngenic
to the Fischer rat strain [90,91], and equivalent to astrocy-
tomas of the World Health Organization (WHO) Grades
III-to-IV (glioblastoma multiforme [GBM]) [55,90,92-94].
In one variation of the methodology, voxel-by-voxel tumor
region of interest concentration and maps have been gen-
erated via co-registration of slices over time for tumor im-
aging over 2 hours under continuous general anesthesia
sedation without the need for intubation and without com-
plications, which has enabled the systematic study of MRI
imageable dendrimer nanoparticle accumulation voxel-by-
voxel over time for theranostic purposes [3,8,12,28,29]
(Figures 3 through 6; Figure 8); whereas, in the other vari-
ation, whole tumor slice volume ROI concentration maps
has been performed for determination of change in whole
tumor contrast agent concentration over a more prolonged
duration of 10 hours upon re-awakening the rodent for
30 minutes in-between 2 minute dynamic scans, also with-
out complications [3,8,29] (Figure 7).
During the course of these laboratory studies, it has
been observed that hemodynamic depression resulting
from being under continuous sedation results in less MRI
imageable dendrimer and theranostic dendrimer nanopar-
ticle accumulation in orthotopic and ectopic solid tumors
of rodents (Figures 3 through 6; Figure 8), which is not
the case in orthotopic and ectopic solid tumors of ro-
dents awakened in-between dynamic scans (Figure 7),
and furthermore, that there is a more significant effect of
anesthesia-induced hemodynamic depression on the accu-
mulation of optimally sized MRI imageable dendrimer
nanoparticles in the interstitium of extra-cranial peripheral
solid tumors as compared to on intra-cranial malignant
gliomas, which underscores the effect of hemodynamic
depression-induced decreased perfusion on the intratu-
moral accumulation of even nanoparticle-sized therapeu-
tics in perfusion-limited hyperpermeable pathologies such
as peripheral solid tumors with greater permeability sur-
face area product (Ktrans).
Conclusions
The realization that nanoparticle-based formulations
could serve as more efficient molecular forms for either
the purpose of imaging, or alternatively, for the purpose
of the treatment of disease states, is relatively long-
standing in the field of translational nanoparticle science,
whereby over the years a variety of functionalizednanoparticles over a spectrum of shapes, sizes and exter-
ior biophysical properties have been investigated for
their suitability for either imaging or therapeutic applica-
tions, but the majority have failed to meet the criterion
of passive selectivity for hyperpermeable pathologies
cum biocompatibility in the physiologic state. In more
recent years, from 2006 to 2009, quantitative high-
resolution dynamic contrast-enhanced MRI at a field
strength of 3 T has been utilized for the detailed imaging
of the accumulation potential of 2 to 14 nanometer-sized
imageable gadolinium chelate-conjugated dendrimer
nanoparticles in the solid tumor interstitium of rodent
malignant gliomas of volumes as small as 20 mm3, which
has been upon bolus intravenous administration over 1 mi-
nute; based on the findings of this research, it has been
discovered that MRI imageable dendrimers are uniquely
biocompatible nanoparticles in that optimally designed
MRI imageable dendrimers within the 7 to 10 nanometer
size range are applicable for the dynamic contrast-
enhanced imaging and concomitant treatment of malig-
nant solid tumors irrespective of tumor permeability
surface area product, and importantly, quantitatively,
while affording the ability to detect solid tumor tissue with
sensitivity and specificity at the translational level.
The translational quantitative dynamic contrast-enhanced
MRI imaging methodology that has been applied, and is dis-
cussed herein, utilizes the measure of the ability of a para-
magnetic MRI imageable dendrimer functionalized with a
small molecule therapeutic to contrast enhance water pro-
ton signal, its molar relaxivity (r1), with the realization that
this measure, in fact, can be appropriately determined
in vitro utilizing T1-weighted Spin-Echo and applied for the
accurate determination of theranostic agent concentration
in blood plasma and in the solid tumor tissue interstitium
overtime on a voxel-by-voxel basis for an accurate non-
invasive assessment of in vivo theranostic pharmacokinetics
utilizing T1-weighted Gradient-Recall Echo.
Based on the observations taken together from the find-
ings of these relatively recent research studies, it can be
surmised that the optimally functionalized biocompatible
theranostic nanoparticle is a non-metal core-based nano-
particle of dendritic architecture in the 7 to 10 nanometer
size range with a therapeutic xenobiotic drug cova-
lently bound inwardly via a labile linkage sensitive to pH
(i.e. hydrazone type) along with a covalently bound an-
ionic moiety exteriorly such as an imageable chelate,
which imparts dense hydrophilic biophysical character to
the exterior. A theranostic nanoparticle based on this de-
sign will demonstrate favorable drug release kinetics upon
passive selective transvascular passage into the hyper-
permeable pathology interstitium during its peak blood
plasma concentration, while there being minimal risk
for systemic or lymphatic hypersensitivity while in sys-
temic circulation.
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anostic quantitative dynamic contrast-enhanced MRI-
based methodology discussed herein based on knowledge
of the optimal nanoparticle size range of 7 to 10 nanome-
ters, density and exterior functionalization necessary for
biocompatible passively selective effective transvascular
delivery of small molecule therapeutics into solid tumors
while maximizing the effectiveness of the approach by
locking in MRI imageable theranostic dendrimer nanopar-
ticle treatments for maximum intratumoral accumulation
favoring intratumoral release of small molecule drug at
peak intratumoral nanoparticle concentration. The further
future objective will be to demonstrate the clinical efficacy
of the fine tuned refined approach within a few years.
It is foreseeably envisioned that the translational thera-
nostic methodology for diagnostic imaging and the con-
comitant treatment of solid malignancies discussed
herein will result in the effective treatment of solid ma-
lignancies, and will also result in the development of ef-
fective transvascular therapies for other disease states of
pathologic hyperpermeability and without.
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